|
|
Article: Sirion Therapeutics Announces Clinical Data to be Presented at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
- Article from:
- PR Newswire
- Article date:
- April 23, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla., April 23 /PRNewswire/ -- Sirion Therapeutics announced today that data on two of the Company's pipeline compounds, ST-601 (difluprednate) and ST-602 (fenretinide), will be presented at the 2007 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. In addition to these presentations, the company will be hosting a reception for ARVO attendees.
ST-601 (difluprednate) is currently being evaluated in two phase III clinical trials in the treatment of ocular inflammation following cataract surgery. ST-601 (difluprednate) was acquired by Sirion last year through an exclusive licensing agreement with Senju ...